

## Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

Patrick M. Reeves<sup>1</sup>, Mojgan A. Abbaslou<sup>1</sup>, Farah R.W. Kools<sup>1</sup>, Kritchai Vutipongsatorn<sup>1</sup>, Xiaoyun Tong<sup>1</sup>, Christina Gavegnano<sup>2</sup>, Raymond F. Schinazi<sup>2</sup> and Mark C. Poznansky<sup>1</sup>

<sup>1</sup> Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA

<sup>2</sup> Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

**Published:** July 13, 2018

**Copyright:** Reeves et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The corrected author name is given below:

**Christina Gavegnano**

Original article: Oncotarget. 2017; 8:94040-94053. <https://doi.org/10.18632/oncotarget.21541>